BIOMAT Database Logo BIOMAT Database Logo

[Antiviral effect of (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl) cytosine on adenovirus]. 2000

H Nakajima, and M Goto, and Y Shimada, and Y Nagamoto, and H Ishiko, and W Inagawa, and N Itoh, and E Uchio, and S Ohno, and K Aoki
Infectious Disease Test Development Department, Mitsubishi Kagaku Bio-Clinical Laboratories, INC, Japan.

OBJECTIVE Adenovirus is the most frequent causative virus of conjunctivitis in Japan. Recently (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl) cytosine (HPMPC) has been promoted as a new drug against adenoviral conjunctivitis. So we examined the antiviral activity of HPMPC against adenoviruses in vitro. METHODS The antiviral activity of HPMPC against adenovirus (Ad) type 3, type 4, type 19, and type 37 isolated from conjunctivial scrapings in Japan and the prototype of adenovirus type 5 was examined by plaque reduction assay using A 549 cells in vitro. RESULTS The 50% inhibitory dose (ID50) of HP-MPC was 3.50 (1.44-4.79) micrograms/ml for Ad type 3, 4.50 (4.17-4.92) micrograms/ml for Ad type 4, 2.11 (1.03-3.13) micrograms/ml for Ad type 5, 1.64 (1.40-2.02) micrograms/ml for Ad type 19, and 2.02 (1.17-2.73) micrograms/ml for type 37. The 50% cytotoxic dose of HPMPC for A 549 cells was 205 micrograms/ml by the deoxythimidine uptake inhibition test, and 537 micrograms/ml by the trypan blue exclusion inhibition test. CONCLUSIONS HPMPC proved to be highly effective in inhibiting replication of adenoviruses at lower concentrations than the cytotoxic level in vitro.

UI MeSH Term Description Entries
D009943 Organophosphorus Compounds Organic compounds that contain phosphorus as an integral part of the molecule. Included under this heading is broad array of synthetic compounds that are used as PESTICIDES and DRUGS. Organophosphorus Compound,Organopyrophosphorus Compound,Organopyrophosphorus Compounds,Compound, Organophosphorus,Compound, Organopyrophosphorus,Compounds, Organophosphorus,Compounds, Organopyrophosphorus
D003596 Cytosine A pyrimidine base that is a fundamental unit of nucleic acids.
D000077404 Cidofovir An acyclic nucleoside phosphonate that acts as a competitive inhibitor of viral DNA polymerases. It is used in the treatment of RETINITIS caused by CYTOMEGALOVIRUS INFECTIONS and may also be useful for treating HERPESVIRUS INFECTIONS. 1-((3-Hydroxy-2-phosphonylmethoxy)propyl)cytosine,1-(3-Hydroxy-2-phosphonylmethoxypropyl)cytosine,Cidofovir Anhydrous,Cidofovir Sodium,Cidofovir, (+-)-isomer,Cidofovir, (R)-isomer,Cidofovir, Sodium Salt,GS 504,GS-504,HPMPC,Vistide,GS504
D000256 Adenoviridae A family of non-enveloped viruses infecting mammals (MASTADENOVIRUS) and birds (AVIADENOVIRUS) or both (ATADENOVIRUS). Infections may be asymptomatic or result in a variety of diseases. Adenoviruses,Ichtadenovirus,Adenovirus,Ichtadenoviruses
D000998 Antiviral Agents Agents used in the prophylaxis or therapy of VIRUS DISEASES. Some of the ways they may act include preventing viral replication by inhibiting viral DNA polymerase; binding to specific cell-surface receptors and inhibiting viral penetration or uncoating; inhibiting viral protein synthesis; or blocking late stages of virus assembly. Antiviral,Antiviral Agent,Antiviral Drug,Antivirals,Antiviral Drugs,Agent, Antiviral,Agents, Antiviral,Drug, Antiviral,Drugs, Antiviral
D063065 Organophosphonates Carbon-containing phosphonic acid compounds. Included under this heading are compounds that have carbon bound to either OXYGEN atom or the PHOSPHOROUS atom of the (P Phosphonate,Phosphonates,Phosphonic Acid Esters,Acid Esters, Phosphonic,Esters, Phosphonic Acid

Related Publications

H Nakajima, and M Goto, and Y Shimada, and Y Nagamoto, and H Ishiko, and W Inagawa, and N Itoh, and E Uchio, and S Ohno, and K Aoki
Structure of 1-(S)-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine; an antiviral agent.
October 1991, Acta crystallographica. Section C, Crystal structure communications,
H Nakajima, and M Goto, and Y Shimada, and Y Nagamoto, and H Ishiko, and W Inagawa, and N Itoh, and E Uchio, and S Ohno, and K Aoki
Pretreatment of the host cell with 1-(S)-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine (HPMPC) is sufficient for its antiviral effect.
May 1992, Acta virologica,
H Nakajima, and M Goto, and Y Shimada, and Y Nagamoto, and H Ishiko, and W Inagawa, and N Itoh, and E Uchio, and S Ohno, and K Aoki
Long-acting therapy of viral retinitis with (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine.
March 1994, The Journal of infectious diseases,
H Nakajima, and M Goto, and Y Shimada, and Y Nagamoto, and H Ishiko, and W Inagawa, and N Itoh, and E Uchio, and S Ohno, and K Aoki
Lack of retinal toxicity of the anticytomegalovirus drug (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl) cytosine.
April 1992, Investigative ophthalmology & visual science,
H Nakajima, and M Goto, and Y Shimada, and Y Nagamoto, and H Ishiko, and W Inagawa, and N Itoh, and E Uchio, and S Ohno, and K Aoki
Liposome-encapsulated (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine for long-acting therapy of viral retinitis.
January 1996, The Journal of infectious diseases,
H Nakajima, and M Goto, and Y Shimada, and Y Nagamoto, and H Ishiko, and W Inagawa, and N Itoh, and E Uchio, and S Ohno, and K Aoki
(S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine, a potent and selective inhibitor of human cytomegalovirus replication.
December 1988, Antimicrobial agents and chemotherapy,
H Nakajima, and M Goto, and Y Shimada, and Y Nagamoto, and H Ishiko, and W Inagawa, and N Itoh, and E Uchio, and S Ohno, and K Aoki
1-[((S)-2-hydroxy-2-oxo-1,4,2-dioxaphosphorinan-5-yl)methyl] cytosine, an intracellular prodrug for (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine with improved therapeutic index in vivo.
October 1994, Antimicrobial agents and chemotherapy,
H Nakajima, and M Goto, and Y Shimada, and Y Nagamoto, and H Ishiko, and W Inagawa, and N Itoh, and E Uchio, and S Ohno, and K Aoki
Treatment of severe laryngeal papillomatosis with intralesional injections of cidofovir [(S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine].
March 1998, Journal of medical virology,
H Nakajima, and M Goto, and Y Shimada, and Y Nagamoto, and H Ishiko, and W Inagawa, and N Itoh, and E Uchio, and S Ohno, and K Aoki
Pretreatment with topical 0.1% (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine inhibits adenovirus type 5 replication in the New Zealand rabbit ocular model.
November 1992, Cornea,
H Nakajima, and M Goto, and Y Shimada, and Y Nagamoto, and H Ishiko, and W Inagawa, and N Itoh, and E Uchio, and S Ohno, and K Aoki
Mechanism of uptake of the phosphonate analog (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine (HPMPC) in Vero cells.
September 1993, Biochemical pharmacology,
Copied contents to your clipboard!